Cognis is launching a new market initiative to educate healthy aging boomers about Tonalin® CLA (conjugated linoleic acid), the “lifetime” ingredient that has been proven to help maintain lean muscle mass while reducing body fat. As people age, they experience “sarcopenia”, a degenerative loss of muscle mass and strength. Sarcopenia is a natural outcome of aging but can be impacted by proper exercise and use of products like Tonalin® CLA.
“Market research tells us that while boomers value a lean, toned body, appearance is just one part of their health equation,” said Sharrann Simmons, Senior Marketing Manager, Cognis Nutrition & Health. “Even more important, they are strongly concerned about maintaining their strength, vitality and independence in daily activities.” Adults lose one percent of their lean body mass each year after the age of 40.
Ms. Simmons explained that the scientifically proven mechanisms of Tonalin® CLA directly address sarcopenia in three ways:
• Reduces up to 10 percent of body fat
• Maintains and increases lean muscle mass
• Prevents fat cells from refilling to stay leaner longer
Tonalin®’s effectiveness has been confirmed by 18 clinical trials; all published in peer-reviewed journals, and is the most researched brand of CLA.
“We invite our customers to join us in pursuing this exciting evolution of the Tonalin® brand.” Ms. Simmons pointed out that Cognis has a solid track record meeting demands of multiple consumer target groups including bodybuilders and fitness enthusiasts. Today, the Tonalin® brand has more than 72 percent market share in North America and is used in consumer products on five continents. “The healthy aging boomer market represents tremendous potential for growth in our brand equity which will be supported by strong co-promotions in multiple media outlets,” she said. The U.S. target audience for healthy aging baby boomers now exceeds 50 million.
Last year, Cognis announced that the U.S. Food and Drug Administration issued a ‘no questions letter’ to Cognis’ GRAS notification (GRN 00232). Tonalin® CLA has achieved FDA GRAS (generally recognized as safe) status and can be safely used in an expanded range of functional foods and beverages. Cognis offers the food and supplements industries the most extensive portfolio of CLA products complemented by innovative application support.
About Tonalin® CLA:
Tonalin® is the original brand of CLA and is an exclusively licensed product of the Cognis Group. CLA is a polyunsaturated, conjugated fatty acid that is a natural part of the human diet, found primarily in meat and dairy products. Cognis produces Tonalin® CLA through a proprietary process that converts linoleic acid from safflowers into CLA, providing the highest quality of CLA available. Tonalin® contains the lowest amount of non-naturally occurring isomers, a patent-protected attribute that provides customers with the highest levels of active CLA isomers. Tonalin® CLA is available in several product forms – oil, water-dispersible powder and emulsions – which offer food manufactures a broad range of options and easy processing for new products. Tonalin® CLA is naturally sourced from safflowers, a sustainable and renewable raw material, and is not labeled as a trans fat.
For more information about Tonalin® CLA or to place an order, visit www.cognis.com and www.tonalin.com, call 800.673.3702, or e-mail firstname.lastname@example.org.
Cognis (www.cognis.com) is a worldwide supplier of innovative specialty chemicals and nutritional ingredients, with a particular focus on the areas of wellness and sustainability. The company employs about 5,600 people, and it operates production sites and service centers in 30 countries. Cognis has dedicated its activities to a high level of sustainability and delivers natural source raw materials and ingredients for food, nutrition and healthcare markets, and the cosmetics, detergents and cleaners industries. Another main focus is on products for a number of other industries, such as coatings and inks, lubricants, as well as agriculture and mining.
Cognis is owned by private equity funds advised by Permira, GS Capital Partners, and SV Life Sciences. In 2008, Cognis recorded sales of about 3 billion euros and an Adjusted EBITDA (operating result) of 351 million euros.